Tricyclic ask1 inhibitors

A compound of formula (IA):

• or a pharmaceutically acceptable salt thereof, wherein:
• ring A is an optionally substituted 5-membered heteroaryl ring;
• ring B is C6-C10 aryl or 5- to 10-membered heteroaryl;
• L1 is optionally substituted C2-C6 alkylene or optionally substituted C2-C6 heteroalkylene;
• L2 is —CO—NH—, —NH—CO—, —SO2—NH—, or —NH—SO2—;
• R1 is optionally substituted C3-C8 cycloalkyl, optionally substituted 6-membered aryl, optionally substituted 5- to 6-membered heteroaryl, optionally substituted 4- to 6-membered heterocyclyl, —CONR11R12 or —SO2NR11R12;
• R11 and R12 are independently selected from the group consisting of hydrogen, optionally substituted C1-C6 alkyl, and optionally substituted C3-C8 cycloalkyl;
• or R11 and R12 are taken together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocyclyl;
• X1, X2, and X3 are independently CR2 or N;
• each R2 is independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C8 cycloalkyl, optionally substituted 6-membered aryl, optionally substituted 5- to 10-membered heteroaryl, optionally substituted 4- to 10-membered heterocyclyl, halo, —NO2, haloalkyl, haloalkoxy, —CN, —O—R3, —S—R3, —N(R3)(R4), —S(═O)—R3, —S(═O)2R3, —S(═O)2—N(R3)(R4), —S(═O)2—O—R3, —N(R3)—C(O)—R4, —N(R3)—C(O)—O—R4, —N(R3)—C(O)—N(R3)(R4), —C(O)—R3, —C(O)—O—R3, —C(O)—N(R3)(R4), or —N(R3)—S(═O)2—R4;
• and
• R3 and R4 are independently selected from the group consisting of hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted C3-C8 cycloalkyl, optionally substituted 6-membered aryl, optionally substituted 5- to 10-membered heteroaryl, and optionally substituted 5- to 10-membered heterocyclyl;
• or R3 and R4 are taken together with the nitrogen atom or with the intervening atoms to which they are attached to form an optionally substituted 4- to 10-membered heterocyclyl.